Inventor
KIRN DAVID
US17 patents
⚠️ This page may combine multiple inventors who share the name “KIRN DAVID”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SILLAJEN BIOTHERAPEUTICS INC
7 patentsUS9919062B2Mar 20, 2018
Oncolytic vaccinia virus cancer therapy
SILLAJEN BIOTHERAPEUTICS INC30 citations93
US9226977B2Jan 5, 2016
Oncolytic vaccinia virus cancer therapy
SILLAJEN BIOTHERAPEUTICS INC25 citations93
US9827278B2Nov 28, 2017
Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses
SILLAJEN BIOTHERAPEUTICS INC2 citations72
US10434169B2Oct 8, 2019
Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
SILLAJEN BIOTHERAPEUTICS INC1 citations59
US9180151B2Nov 10, 2015
Oncolytic vaccinia virus combination cancer therapy
SILLAJEN BIOTHERAPEUTICS INC2 citations59
US10767166B2Sep 8, 2020
Methods and compositions for production of vaccina virus
SILLAJEN BIOTHERAPEUTICS INC0 citations51
US10202581B2Feb 12, 2019
Methods and compositions for production of vaccinia virus
SILLAJEN BIOTHERAPEUTICS INC0 citations51
KIRN DAVID
6 patentsUS8980246B2Mar 17, 2015
Oncolytic vaccinia virus cancer therapy
KIRN DAVID17 citations91
US8747837B2Jun 10, 2014
Oncolytic vaccinia virus combination cancer therapy
KIRN DAVID18 citations89
US8329164B2Dec 11, 2012
Methods and compositions concerning poxviruses and cancer
KIRN DAVID10 citations79
US9719105B2Aug 1, 2017
Methods and compositions for production of vaccinia virus
KIRN DAVID2 citations72
US9180149B2Nov 10, 2015
Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses
KIRN DAVID4 citations72
US9919047B2Mar 20, 2018
Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
KIRN DAVID5 citations70
ONYX PHARMA INC
3 patentsUS6296845B1Oct 2, 2001
Selective killing and diagnosis of p53+ neoplastic cells
ONYX PHARMA INC31 citations86
US6080578AJun 27, 2000
Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia
ONYX PHARMA INC24 citations85
US6133243AOct 17, 2000
Liposomal-viral DNA complexes for treating disease
ONYX PHARMA INC17 citations83